Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: Role of the pharmacist

Journal of Managed Care Pharmacy

Volumn 15, Issue 6 SUPPL. B, 2009, Pages

  Johnson, Samuel G ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DABIGATRAN; DRONEDARONE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ASTHMA; BLEEDING; CARDIAC PATIENT; CASE MANAGEMENT; CLINICAL PRACTICE; CORNEA DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MONITORING; DRUG WITHDRAWAL; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; MANAGED CARE; MEDICAL RECORD; OPTIC NEURITIS; PHARMACEUTICAL CARE; PHARMACIST; QT PROLONGATION; RECURRENT DISEASE; REVIEW; STROKE; THROMBOEMBOLISM; THYROID DISEASE; VENOUS THROMBOEMBOLISM;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CASE MANAGEMENT; COST-BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS, PHARMACEUTICAL; HOSPITAL COSTS; HUMANS; MANAGED CARE PROGRAMS; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 70349611532     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.s6-b.19     Document Type: Review

References (32)

1. Rx for Safety. Glossary. Available at: www.rxforsafety.com/glossary/ index.html. Accessed April 9, 2009.
2. Duke Clinical Research Institute. Glossary. Available at: http://www.dcri.duke.edu/patient/glossary.jsp. Accessed July 25, 2009.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-75. Available at: http://jama.ama-assn.org/cgi/ reprint/285/18/2370. Accessed July 25, 2009.
4. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18(6):628-633 (Pubitemid 46800517)
5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25. Available at: http://circ.ahajournals.org/cgi/reprint/114/2/119. Accessed July 25, 2009.
6. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21(10):1693-1699 (Pubitemid 41505035)
7. Anonymous. FDA advisory committee recommends approval of Multaq (dronedarone). Medical News Today. March 19, 2009. Available at: http://www.medicalnewstoday.com/articles/142834.php. Accessed July 26, 2009.
8. Walker EP. Rivaroxaban recommended for approval by FDA advisory panel. Medpage Today. March 19, 2009. Available at: http://www.medpagetoday.com/ ProductAlert/Prescriptions/13353. Accessed July 24, 2009.
9. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-87. Available at: http://content.nejm.org/cgi/reprint/358/25/ 2678.pdf. Accessed July 25, 2009. (Pubitemid 351860860)
10. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29(2):155-65. Available at: http://eurheartj.oxfordjournals.org/cgi/ reprint/29/2/155. Accessed July 25, 2009.
11. Newberry M. The lifestyle chronicles - the 80/20 rule. April 4, 2006. Available at: http://fixinghealth.blogspot.com/2006/04/lifestyle-chronicles- 8020-rule.html. Accessed July 25, 2009.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70. Available at: http://jama.ama-assn.org/cgi/reprint/285/22/2864. Accessed July 25, 2009. (Pubitemid 32537350)
13. Domurat ES. Diabetes managed care and clinical outcomes: the Harbor City, California Kaiser Permanente Diabetes Care System. Am J Manag Care. 1999;5(10):1299-307. Available at: http://www.ajmc.com/media/pdf/ AJMC1999octDomurat1299-07.pdf. Accessed July 25, 2009.
14. McFadden ER Jr, Elsanadi N, Dixon L, et al. Protocol therapy for acute asthma: therapeutic benefits and cost savings. Am J Med. 1995;99(6):651-661 (Pubitemid 26006447)
15. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61(10):1042-49. Available at: http://archpsyc.ama-assn.org/cgi/ reprint/61/10/1042. Accessed July 25, 2009. (Pubitemid 39336538)
16. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167(3):246-52. Available at: http://archinte.ama-assn.org/cgi/reprint/167/ 3/246. Accessed July 25, 2009. (Pubitemid 46256541)
17. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156(20):2311-2316 (Pubitemid 26395544)
18. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967-73. Available at: http://archinte.ama-assn.org/cgi/reprint/160/7/967. July 25, 2009.
19. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):546S-92S. Available at: http://www.chestjournal.org/content/133/6-suppl/546S.full.pdf+html. Accessed July 25, 2009.
20. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641-47. Available at: http://archinte.ama-assn.org/cgi/reprint/158/15/1641. Accessed July 25, 2009. (Pubitemid 28371187)
21. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127(5):1515-22. Available at: http://www.chestjournal.org/content/127/5/1515.full.pdf+html. Accessed July 25, 2009. (Pubitemid 46218774)
22. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995;15(6):732-739
23. Garabedian-Ruffalo SM, Gray DR, Sax MJ, et al. Retrospective evaluation of a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm. 1985;42(2):304-308 (Pubitemid 15162740)
24. Donovan JL, Drake JA, Whittaker P, Tran MT. Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis. 2006;22(1):23-30. (Pubitemid 43922998)
25. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004;10(2):159-65. Available at: http://www.amcp.org/data/jmcp/Contemporary%20Subjects-159-165.pdf.
26. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1-148. Available at: http://content.onlinejacc.org/cgi/reprint/48/3/e1.pdf. Accessed July 25, 2009.
27. Stewart K, Loftus S, DeLisle S. Prescription of amiodarone through a computerized template that includes both decision support and executive functions improves the monitoring for toxicities. AMIA Annu Symp Proc. 2003;1020. Available at: http://www2.amia.org/pubs/proceedings/symposia/2003/ 404.pdf. Accessed July 25, 2009.
28. Sanoski CA, Schoen MD, Gonzalez RC, Avitall B, Bauman JL. Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic. Pharmacotherapy. 1998;18(6 Pt 2):146S-51S. (Pubitemid 28533867)
29. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-354. Available at: http://circ.ahajournals.org/cgi/reprint/114/ 7/e257. Accessed July 25, 2009.
30. McEvoy GK, ed. Amiodarone hydrochloride. In: AHFS Drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1682-1697
31. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-438 (Pubitemid 36560714)
32. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46(1):21-28. (Pubitemid 43024117)